Zacks12d agobearish
Biogen Q2 Earnings: Can New Drugs Counter Falling MS Sales?BIIB heads into Q2 results with new launches expected to offset weaker MS drug sales as investors watch Leqembi trends and the Apellis deal impact.
News
High-signal headlines only - macro events, earnings, M&A, regulatory. Listicles and analyst clickbait filtered out by default. Refreshed hourly.
514last 24h
2492last 7d
477● bullish (7d)
256● bearish (7d)
197publishers